- Home
- Heart Failure
Heart Failure
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
Incorporating GDMT and PRO Endpoints for Personalised HF Management
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
Changing Paradigms in Therapy to Unmet Needs
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF